Skip to content
The Policy VaultThe Policy Vault

Vykat XR (diazoxide choline) — Blue Cross Blue Shield of New Mexico

Other FDA labeled indications for Vykat XR

Initial criteria

  • 1. ONE of the following:
  • A. The patient has a diagnosis of Prader-Willi syndrome AND BOTH of the following:
  • 1. The patient has hyperphagia AND
  • 2. The patient’s diagnosis has been confirmed by genetic testing indicating mutation on chromosome 15 (medical records required) OR
  • B. The patient has another FDA labeled indication for the requested agent and route of administration AND
  • 2. If the patient has an FDA labeled indication, then ONE of the following:
  • A. The patient’s age is within FDA labeling for the requested indication for the requested agent OR
  • B. There is support for using the requested agent for the patient’s age for the requested indication AND
  • 3. The prescriber is a specialist in the area of the patient’s diagnosis (e.g., endocrinologist, geneticist), or has consulted with such a specialist AND
  • 4. The patient does NOT have any FDA labeled contraindications to the requested agent
  • OR
  • The request is for a BCBS NM Fully Insured or NM HIM member and ALL of the following:
  • A. The patient does NOT have any FDA labeled contraindications to the requested agent AND
  • B. The requested indication is a rare disease AND
  • C. ONE of the following:
  • 1. The patient has another FDA labeled indication for the requested agent and route of administration OR
  • 2. The patient has another indication supported in compendia for the requested agent and route of administration
  • OR
  • ALL of the following (for OH Fully Insured or HIM Shop members):
  • A. The member resides in Ohio AND
  • B. The plan is Fully Insured or HIM Shop (SG) AND
  • C. The patient does NOT have FDA labeled contraindications to the requested agent AND
  • D. ONE of the following:
  • 1. The patient has another FDA labeled indication for the requested agent and route of administration OR
  • 2. The patient has another indication supported in compendia (DrugDex level 1–2B; AHFS-DI supportive narrative; NCCN 1–2A; Clinical Pharmacology supportive; LexiDrugs evidence level A) OR
  • 3. The prescriber has submitted TWO articles from major peer-reviewed medical journals (e.g., JAMA, NEJM, Lancet) showing safety and efficacy (case studies not acceptable)

Reauthorization criteria

  • 1. The patient has been previously approved for the requested agent through the plan’s Prior Authorization process AND
  • 2. The patient has had clinical benefit with the requested agent AND
  • 3. The prescriber is a specialist in the area of the patient’s diagnosis (e.g., endocrinologist, geneticist), or has consulted with such a specialist AND
  • 4. The patient does NOT have any FDA labeled contraindications to the requested agent

Approval duration

initial: BCBSIL/BCBSMT 12 months; others 4 months; renewal 12 months